Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines:
- Emergex has successfully generated a 1st generation human specific MHC-Class I CD8 peptide ‘ligandome’ library for Dengue, Influenza, Zika, Hepatitis B and Francisella tularensis, for the most commonly occurring human alleles. This allele coverage would allow greater than 95% population coverage. The ‘ligandome’ library contains encrypted peptide data to instruct the immune system to alter the initial ‘set-point’ of response on first exposure and potentially reduce disease severity but still allow natural immunity to provide long term protection.
- Emergex’s vaccines do not need an adjuvant and potentially avoid the limitations like the allergic, autoimmune or antibody mediated side effects associated with traditional vaccines.
- These validated peptides are combined with an extremely small (quantum) gold nanoparticle that can directly deliver them to the naive immune system and program the immune system to eliminate pathogen infected cells upon subsequent exposure and infection. It is the combination of these technologies that produces a ‘set-point’ vaccine, capable of delivering the right peptides to the right place, in order to produce a strong T-cell immune response that will target and kill infected cells.
- Emergex’s vaccines are suited to be administered by novel microneedles’ technologies.
